Elizabeth Farrant


New Path Molecular Research


Elizabeth has a degree in chemistry and a PhD in natural product synthesis. She started her career as a chemist in discovery research at SmithKline Beecham and since then she has worked in scientific and leadership roles in GSK and Pfizer. In 2011 she switched to become Chief Business Officer at a Pfizer spin out and in 2015 became one of the founders of start-up New Path Molecular, a spin out from the laboratory of Prof Seven Ley. She brings a 20-year track record of technology development and commercialisation in the pharmaceutical industry and has also published in chemical technologies, flow chemistry and lead diversification.